Skip to main content

Table 1 IC 50 in nM of single agent treatments in HS-SY-II and SYO-I

From: Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells

Treatments

HS-SY-II

SYO-I

Ridaforolimus

10.9 ± 2.7 nM*

23.1 ± 4.6 nM*

Vorinostat

440 ± 46.7 nM

561 ± 40.4 nM

Doxorubicin

9.4 ± 1.4 nM

7.4 ± 1.1 nM

Melphalan

687 ± 117.6 nM

859 ± 113.7 nM

  1. Data presented in Table 1 represent the mean ± SE from at least 8 independent experiments.
  2. *Indicates statistical significance of p < 0.05, when the IC50 of a given agent was compared between the two cell lines.
Back to article page

BMC Research Notes

ISSN: 1756-0500

Contact us